Literature DB >> 9209497

Activation of protein kinase C attenuates early signals in Fas-mediated apoptosis.

M C Ruiz-Ruiz1, M Izquierdo, G de Murcia, A López-Rivas.   

Abstract

Activation of protein kinase C (PKC) has been reported to inhibit Fas (APO-1, CD95)-mediated apoptosis in different cellular systems. Human Jurkat leukemic T cells express the Fas antigen in the cell membrane and undergo apoptosis upon cross-linking by anti-Fas monoclonal antibodies (mAb). Cleavage of the apoptosis-associated protease CPP32 and its substrate poly(ADP-ribose)polymerase are observed after the engagement of Fas antigen with mAb. In this report, we show that all these effects are substantially inhibited by the activation of PKC with a phorbol ester. Bisindolylmaleimide, an inhibitor of PKC, prevents phorbol ester-induced down-regulation of Fas signaling. Inhibition of Fas-mediated cell death by phorbol ester is also observed in other human leukemic T cell lines. Cross-linking of Fas antigen by mAb results in the rapid increase in tyrosine phosphorylation of several protein substrates which is further elevated in the presence of the protein tyrosine phosphatase inhibitor, orthovanadate. Furthermore, orthovanadate markedly enhances the cell death response to Fas mAb in different human leukemic T cell lines and human T cell blasts. These effects of orthovanadate on early tyrosine phosphorylation and cell death are clearly diminished by PKC activation. These results strongly suggest that tyrosine phosphorylation is involved in Fas signaling in apoptosis and that PKC plays a negative role in Fas-mediated apoptosis by counteracting at a very early stage the signals generated following cross-linking of this receptor.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9209497     DOI: 10.1002/eji.1830270622

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

1.  Activation of CD95 (APO-1/Fas) signaling by ceramide mediates cancer therapy-induced apoptosis.

Authors:  I Herr; D Wilhelm; T Böhler; P Angel; K M Debatin
Journal:  EMBO J       Date:  1997-10-15       Impact factor: 11.598

2.  CD95 triggers Orai1-mediated localized Ca2+ entry, regulates recruitment of protein kinase C (PKC) β2, and prevents death-inducing signaling complex formation.

Authors:  Nadine Khadra; Laurence Bresson-Bepoldin; Aubin Penna; Benjamin Chaigne-Delalande; Bruno Ségui; Thierry Levade; Anne-Marie Vacher; Josy Reiffers; Thomas Ducret; Jean-François Moreau; Michael D Cahalan; Pierre Vacher; Patrick Legembre
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

3.  The changes of protein kinase C activity in peripheral blood lymphocytes in the patients with obstructive jaundice and the implication.

Authors:  J Wang; Q Zou; S Zou
Journal:  J Tongji Med Univ       Date:  2001

4.  Roles of protein kinase C and fructose in hepatic injury caused by obstructive jaundice.

Authors:  Jianming Wang; Hui Wang; Baolai Xiao; Shengquan Zou
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

5.  Inhibition of Fas-mediated apoptotic cell death of murine T lymphocytes in a mouse model of immunosenescence in linkage to deterioration in cell membrane raft function.

Authors:  Toshihiro Yokoyama; Jun Du; Yoshiyuki Kawamoto; Haruhiko Suzuki; Izumi Nakashima
Journal:  Immunology       Date:  2004-05       Impact factor: 7.397

6.  Regulation of the PKCθ-NF-κB Axis in T Lymphocytes by the Tumor Necrosis Factor Receptor Family Member OX40.

Authors:  Takanori So; Michael Croft
Journal:  Front Immunol       Date:  2012-05-28       Impact factor: 7.561

7.  Mitogen-activated protein kinase kinase antagonized fas-associated death domain protein-mediated apoptosis by induced FLICE-inhibitory protein expression.

Authors:  J H Yeh; S C Hsu; S H Han; M Z Lai
Journal:  J Exp Med       Date:  1998-11-16       Impact factor: 14.307

Review 8.  RKIP Pleiotropic Activities in Cancer and Inflammatory Diseases: Role in Immunity.

Authors:  Roni Touboul; Stavroula Baritaki; Apostolos Zaravinos; Benjamin Bonavida
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.